LGND LIGAND PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 886163 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.0%
TTM net income YoY5.9%
TTM EPS YoY9.7%
Revenue 3-yr CAGR18.2%
Net income 3-yr CAGR46.2%
Margins
Gross margin—
Operating margin9.5%
Net margin20.3%
FCF margin35.7%
EBITDA margin23.2%
Returns
ROE5.4%
ROA2.8%
ROIC (approx.)1.4%
Asset turnover0.14x
Leverage & solvency
Liabilities / assets57.0%
Debt / equity1.17x
Current ratio1.22x
Interest coverage2.94x
Cash quality & payout
Operating cash flow / net income1.77x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $268.09M | $167.13M | $131.31M | $196.25M | $241.54M |
| R&D expense | $81.18M | $21.43M | $24.54M | $36.08M | $32.10M |
| SG&A expense | $92.45M | $78.65M | $52.79M | $70.06M | $46.79M |
| Operating income | $41.00M | -$22.61M | $11.94M | $3.04M | $103.85M |
| Interest expense | $4.71M | $3.04M | $656,000 | $1.80M | $19.62M |
| Pretax income | $158.96M | $2.52M | $63.66M | $36.01M | $72.20M |
| Income tax | $34.51M | $6.55M | $9.84M | $41.23M | -$4.15M |
| Net income | $124.45M | -$4.03M | $52.15M | -$33.36M | $57.14M |
| EBITDA | $74.78M | $12.63M | $48.46M | $54.57M | $154.92M |
| EPS (basic) | 6.44 | -0.22 | 3.02 | -1.98 | 3.44 |
| EPS (diluted) | 6.13 | -0.22 | 2.94 | -1.98 | 3.31 |
| Weighted avg. shares (diluted) | 20.29M | 18.29M | 17.76M | 16.87M | 17.25M |
| Balance sheet | |||||
| Cash & equivalents | $174.93M | $72.31M | $22.95M | $45.01M | $19.52M |
| Short-term investments | $558.59M | $183.86M | $147.35M | $166.86M | $321.59M |
| Receivables | $59.60M | $38.38M | $32.92M | $30.42M | $85.45M |
| Inventory | $9.13M | $14.11M | $23.97M | $13.29M | $27.33M |
| Current assets | $832.27M | $331.56M | $237.43M | $263.60M | $464.75M |
| PP&E, net | $3.57M | $15.13M | $15.61M | $12.48M | $13.19M |
| Goodwill | $101.54M | $105.25M | $103.37M | $0 | $105.67M |
| Intangibles | $225.44M | $266.65M | $299.61M | $342.45M | $376.69M |
| Total assets | $1.56B | $941.77M | $787.22M | $762.67M | $1.30B |
| Current liabilities | $37.45M | $37.11M | $16.78M | $98.81M | $41.66M |
| Long-term debt | $446.19M | $0 | — | — | — |
| Total debt | $446.19M | $0 | — | — | — |
| Total liabilities | $543.42M | $111.33M | $86.30M | $165.18M | $476.43M |
| Shareholders' equity | $1.02B | $830.44M | $700.91M | $597.49M | $821.16M |
| Net debt | $271.26M | -$72.31M | — | — | — |
| Shares outstanding | 19.77M | 19.11M | 17.56M | 16.95M | 16.77M |
| Cash flow statement | |||||
| Operating cash flow | $49.36M | $97.05M | $49.58M | $137.85M | $78.80M |
| Capital expenditure | $452,000 | $1.82M | $3.52M | $17.92M | $8.76M |
| Free cash flow | $48.91M | $95.23M | $46.06M | $119.93M | $70.04M |
| Investing cash flow | -$377.32M | -$143.66M | -$11.68M | $163.62M | $30.52M |
| Financing cash flow | $428.22M | $97.14M | -$59.95M | -$275.99M | -$137.76M |
| Depreciation & amortization | $33.77M | $35.24M | $36.52M | $51.53M | $51.07M |
| Stock-based compensation | $46.85M | $41.09M | $25.74M | $60.28M | $38.78M |
| Share buybacks | $15.00M | $0 | $0 | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.